Alembic enters into license agreement with Accu-Break of US

Vadodara based Alembic Pharmaceuticals has entered into a development and license agreement with Florida based Accu-Break Pharmaceuticals Inc. USA (ABP) to develop new brand products using ABP's innovative tablet technologies.

ABP patented Accu-Break can be split easily by hand into smaller doses to provide maximum flexibility.

This makes it easier and safer for patients and caregivers to adjust their dosage. The first product for which ABP will seek marketing approval from the US Food and Drugs Administration (USFDA) is an Accu-Break formatted version of the popular anti-coagulant medication warfarin, Alembic said in a statement to the Bombay Stock Exchange (BSE).

Based in Plantation, Florida, ABP is a technology licensing and product development company.

The company has a broad patent portfolio of 48 patents already issued and 22 patents pending worldwide.

It is currently licensing the Accu-Break technologies to other parties for product development.

While the focus is on the US market, the products would also be sold in India.

The products are likely to hit the market in three to four years time.

Earlier in June, another US based company Pfizer had dragged Alembic to court over a patent infringement issue. Alembic Pharmaceuticals and US-based Breckenridge Pharmaceutical had been named co-defendants in a Para IV lawsuit filed by Pfizer over alleged patent infringement with regards to its anti-depressant drug under the brand name Pristiq.